Simultaneous gene transduction and silencing using stimuli-responsive viral/nonviral chimeric nanoparticles

Biomaterials

Volumn 33, Issue 11, 2012, Pages 3316-3323

  Cho, Soo Kyung ^a   Kwon, Young Jik ^a,b  

^a University of California at Irvine   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adeno associated virus; Combined viral nonviral chimeric nanoparticle; Gene transfer; Simultaneous expression and silencing; SiRNA; Stimuli responsive delivery

Indexed keywords

ADENO-ASSOCIATED VIRUS; CLINICAL TRIAL; CORE-SHELL; GENE DELIVERY; GENE TRANSDUCTION; IMMUNE RESPONSE; IMMUNE SYSTEMS; IMMUNOGENICITY; INTRACELLULAR TRAFFICKING; MULTI-MODAL; MULTIPLE GENES; NONVIRAL; NONVIRAL VECTORS; SIALIC ACIDS; SIMULTANEOUS EXPRESSION AND SILENCING; SIRNA; STIMULI-RESPONSIVE; TARGET GENES; TARGETED GENE DELIVERY; THERAPEUTIC EFFECTS; TUNABILITIES; VIRAL VECTORS;

BACTERIOPHAGES; CARBOXYLIC ACIDS; CYTOLOGY; DRUG THERAPY; GENE EXPRESSION; GENE TRANSFER; IMMUNOLOGY; NANOPARTICLES;

GENE THERAPY;

CHIMERIC NANOPARTICLE; DNA; NANOPARTICLE; SIALIC ACID; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS VECTOR;

ARTICLE; CELL MIGRATION; CYTOPLASM; ENCAPSULATION; GENE DELIVERY SYSTEM; GENE INACTIVATION; GENE SILENCING; GENE TARGETING; GENETIC TRANSDUCTION; IMMUNE SYSTEM; NONHUMAN; PRIORITY JOURNAL; STIMULUS RESPONSE; THERAPY EFFECT; VIRUS PARTICLE;

ADENOVIRIDAE; GENE SILENCING; GENE TARGETING; NANOCAPSULES; TRANSDUCTION, GENETIC; VIRION;

ADENO-ASSOCIATED VIRUS;

EID: 84856569430     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.01.027     Document Type: Article

References (57)

1. Thomas C.E., Ehrhardt A., Kay M.A. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 2003, 4(5):346-358.
2. Manning W.C., Zhou S., Bland M.P., Escobedo J.A., Dwarki V. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum Gene Ther 1998, 9(4):477-485.
3. Halbert C.L., Rutledge E.A., Allen J.M., Russell D.W., Miller A.D. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. JVirol 2000, 74(3):1524-1532.
4. O'Riordan C.R., Lachapelle A.L., Vincent K.A., Wadsworth S.C. Scaleable chromatographic purification process for recombinant adeno associated virus (rAAV). JGene Med 2000, 2(6):444-454.
5. Clark K.R., Liu X., McGrath J.P., Johnson P.R. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther 1999, 10(6):1031-1039.
6. Zolotukhin S., Byrne B.J., Mason E., Zolotukhin I., Potter M., Chesnut K., et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 1999, 6(6):973-985.
7. Eglon M.N., Duffy A.M., O'Brien T., Strappe P.M. Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography. JGene Med 2009, 11(11):978-989.
8. Ogawara K.I., Rots M.G., Kok R.J., Moorlag H.E., van Loenen A.M., Meijer D.K.F., et al. Novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells invitro and invivo. Hum Gene Ther 2004, 15(5):433-443.
9. Xie Q., Bu W., Bhatia S., Hare J., Somasundaram T., Azzi A., et al. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA 2002, 99(16):10405-10410.
10. Lin T., Chen Z., Usha R., Stauffacher C.V., Dai J.B., Schmidt T., et al. The refined crystal structure of cowpea mosaic virus at 2.8 å resolution. Virol 1999, 265(1):20-34.
11. Carlisle R.C., Benjamin R., Briggs S.B., Sumner-Jones S., McIntosh J., Gill D., et al. Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. JGene Med 2008, 10(4):400-411.
12. Chatterji A., Ochoa W.F., Paine M., Ratna B.R., Johnson J.E., Lin T. New Addresses on an addressable virus nanoblock: uniquely reactive Lys residues on Cowpea Mosaic virus. Chem Biol 2004, 11(6):855-863.
13. Arruda V.R., Favaro P., Finn J.D. Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther 2009, 17(9):1492-1503.
14. Zhong L., Li B., Mah C.S., Govindasamy L., Agbandje-McKenna M., Cooper M., et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA 2008, 105(22):7827-7832.
15. Kreppel F., Gackowski J., Schmidt E., Stefan K. Combined genetic and chemical capsid modifications enable flexible and efficient de- and retargeting of adenovirus vectors. Mol Ther 2005, 12(1):107-117.
16. Lanciotti J., Song A., Doukas J., Sosnowski B., Pierce G., Gregory R., et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003, 8(1):99-107.
17. Kim P.H., Sohn J.H., Choi J.W., Jung Y., Kim S.W., Haam S., et al. Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin. Biomaterials 2011, 32(9):2314-2326.
18. Singh R., Al-Jamal K.T., Lacerda L., Kostarelos K. Nanoengineering artificial lipid envelopes around adenovirus by self-assembly. ACS Nano 2008, 2(5):1040-1050.
19. Zhong Z., Shi S., Han J., Zhang Z., Sun X. Anionic liposomes increase the efficiency of adenovirus-mediated gene transfer to Coxsackie-adenovirus receptor deficient cells. Mol Pharmaceutics 2009, 7(1):105-115.
20. Ramsey J.D., Vu H.N., Pack D.W. Atop-down approach for construction of hybrid polymer-virus gene delivery vectors. JControl Release 2010, 144(1):39-45.
21. Gary K.L., Narendra M., Brian K., David V.S. PEG conjugation moderately protects adeno-associated viral vectors against antibody neutralization. Biotechnol Bioeng 2005, 92(1):24-34.
22. Subr V., Kostka L., Selby-Milic T., Fisher K., Ulbrich K., Seymour L.W., et al. Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. JControl Release 2009, 135(2):152-158.
23. Mok H., Palmer D.J., Ng P., Barry M.A. Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses. Mol Ther 2005, 11(1):66-79.
24. Heemskerk B., Veltrop-Duits L.A., van Vreeswijk T., ten Dam M.M., Heidt S., Toes R.E.M., et al. Extensive cross-reactivity of CD4+ adenovirus-specific T cells: implications for immunotherapy and gene therapy. JVirol 2003, 77(11):6562-6566.
25. Rainer H., Felix K. Polymer therapeutics: concepts and applications. Angew Chem Int Ed 2006, 45(8):1198-1215.
26. Perrett S., Golding M., Williams W.P. Asimple method for the preparation of liposomes for pharmaceutical applications: characterization of the liposomes. JPharm Pharmacol 1991, 43(3):154-161.
27. Shigeru K., Yuriko H., Mitsuru H. Nonviral approaches for targeted delivery of plasmid DNA and oligonucleotide. JPharm Sci 2008, 97(2):726-745.
28. Davis M.E., Chen Z., Shin D.M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008, 7(9):771-782.
29. Morille M., Passirani C., Vonarbourg A., Clavreul A., Benoit J.-P. Progress in developing cationic vectors for non-viral systemic gene therapy against cancer. Biomaterials 2008, 29(24-25):3477-3496.
30. Luo D., Saltzman W.M. Synthetic DNA delivery systems. Nat Biotechnol 2000, 18(1):33-37.
31. Dash P.R., Read M.L., Barrett L.B., Wolfert M.A., Seymour L.W. Factors affecting blood clearance and invivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther 1999, 6(4):643-650.
32. Kelly P.N., Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011, 18(9):1414-1424.
33. Shim M.S., Kwon Y.J. Controlled cytoplasmic and nuclear localization of plasmid DNA and siRNA by differentially tailored polyethylenimine. JControl Release 2009, 133(3):206-213.
34. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Ann Rev Biomed Eng 2006, 8:343-375.
35. Cho S.K., Kwon Y.J. Polyamine/DNA polyplexes with acid-degradable polymeric shell as structurally and functionally virus-mimicking nonviral vectors. JControl Release 2011, 150(3):287-297.
36. Ko I.K., Ziady A., Lu S., Kwon Y.J. Acid-degradable cationic methacrylamide polymerized in the presence of plasmid DNA as tunable non-viral gene carrier. Biomaterials 2008, 29(28):3872-3881.
37. Kwon Y.J., Standley S.M., Goodwin A.P., Gillies E.R., Fréchet J.M.J. Directed antigen presentation using polymeric microparticulate carriers degradable at lysosomal pH for controlled immune responses. Mol Pharmaceutics 2005, 2(1):83-91.
38. Blacklow N.R., Hoggan M.D., Sereno M.S., Brandt C.D., Kim H.W.H.A., Parrott R.H., et al. Aseroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 1971, 94(4):359-366.
39. Schultz B.R., Chamberlain J.S. Recombinant adeno-associated virus transduction and integration. Mol Ther 2008, 16(7):1189-1199.
40. Shike H., Shimizu C., Kanegaye J.T., Foley J.L., Schnurr D.P., Wold L.J., et al. Adenovirus, adeno-associated virus and Kawasaki disease. Pediatr Infect Dis J 2005, 24(11):1011-1014.
41. Weitzman M.D., Kyöstiö S.R., Kotin R.M., Owens R.A. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. Proc Natl Acad Sci USA 1994, 91(13):5808-5812.
42. Coura R., Nardi N. The state of the art of adeno-associated virus-based vectors in gene therapy. JVirol 2007, 4(1):99-105.
43. Le H.T., Yu Q.-C., Wilson J.M., Croyle M.A. Utility of PEGylated recombinant adeno-associated viruses for gene transfer. JControl Release 2005, 108(1):161-177.
44. Sonawane N.D., Szoka F.C., Verkman A.S. Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. JBiol Chem 2003, 278(45):44826-44831.
45. Hu Y., Litwin T., Nagaraja A.R., Kwong B., Katz J., Watson N., et al. Cytosolic delivery of membrane-impermeable molecules in dendritic cells using pH-responsive core-shell nanoparticles. Nano Lett 2007, 7(10):3056-3064.
46. Su Z., Wang Q.A. Hierarchical assembly process to engineer a hydrophobic core for virus-like particles. Angew Chem Int Ed 2010, 49(52):10048-10050.
47. Uchida M., Klem M.T., Allen M., Suci P., Flenniken M., Gillitzer E., et al. Biological containers: protein cages as multifunctional nanoplatforms. Adv Mater 2007, 19(8):1025-1042.
48. Dixit S.K., Goicochea N.L., Daniel M.C., Murali A., Bronstein L., De M., et al. Quantum dot encapsulation in viral capsids. Nano Lett 2006, 6(9):1993-1999.
49. de la Escosura A., Janssen P.G.A., Schenning A.P.H.J., Nolte R.J.M., Cornelissen J.J.L.M. Encapsulation of DNA templated chromophore assemblies within virus protein nanotubes. Angew Chem Int Ed 2010, 122(31):5463-5466.
50. Fischlechner M., Zschönig O., Hofmann J., Donath E. Engineering virus functionalities on colloidal polyelectrolyte lipid composites. Angew Chem Int Ed 2005, 117(19):2952-2955.
51. Kwak M., Minten I.J., Anaya D.M., Musser A.J., Brasch M., Nolte R.J.M., et al. Virus-like particles templated by DNA micelles: a general method for loading virus nanocarriers. JAm Chem Soc 2010, 132(23):7834-7835.
52. Loo L.N., Guenther R.H., Lommel S.A., Franzen S. Encapsidation of nanoparticles by red clover necrotic mosaic virus. JAm Chem Soc 2007, 129(36):11111-11117.
53. Blumenthal R., Clague M.J., Durell S.R., Epand R.M. Membrane fusion. Chem Rev 2002, 103(1):53-70.
54. Wendtner C.M., Kofler D.M., Theiss H.D., Kurzeder C., Buhmann R., Schweighofer C., et al. Efficient gene transfer of CD40 ligand into primary B-CLL cells using recombinant adeno-associated virus (rAAV) vectors. Blood 2002, 100(5):1655-1661.
55. Theiss H.D., Kofler D.M., Büning H., Aldenhoff A.-L., Kaess B., Decker T., et al. Enhancement of gene transfer with recombinant adeno-associated virus (rAAV) vectors into primary B-cell chronic lymphocytic leukemia cells by CpG-oligodeoxynucleotides. Exp Hematol 2003, 31(12):1223-1229.
56. Ng A.K. Diffuse large B-Cell lymphoma. Sem Radiat Oncol 2007, 17(3):169-175.
57. Razi N., Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc Natl Acad Sci USA 1998, 95(13):7469-7474.